-
AbbVie’s Allergan Aesthetics Launches Juvéderm VOLUX in China
•
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the official market launch of its Juvéderm VOLUX dermal filler product in China. Juvéderm VOLUX is a hyaluronic acid-based product specifically designed for contouring the lower jaw area. It is used for injection onto the facial periosteum to enhance the…
-
Sihuan Pharmaceutical Sees Aesthetics and Biopharma Growth Amid Overall Revenue Dip
•
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), a leading pharmaceutical company in China, has released its financial report for the first half of 2024, highlighting a strategic pivot towards medical aesthetics and biopharmaceuticals. The company’s “medical aesthetics + innovative drug” dual-driven strategy has been instrumental in this transformation. For the…
-
Fosun Pharmaceutical’s Daxxify Receives NMPA Approval for Aesthetic Use in China
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National Medical Products Administration (NMPA) has granted market approval for its product Daxxify (daxibotulinumtoxin, RT002). This type A botulinum toxin is now approved for the temporary improvement of moderate to severe eyebrow wrinkles in adults in…
-
Huadong Medicine Expands Global Footprint with Launch of Aesthetic Injection MaiLi in Singapore
•
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced the international expansion of its medical aesthetics portfolio with the launch of its high-end aesthetic injection product, MaiLi, in Singapore. This marks another milestone in the company’s global foray into the medical aesthetics sector. MaiLi is a premium…
-
Sirnaomics Ltd Forms JV with Gore Range Capital to Pioneer Medical Aesthetics Innovations
•
Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company specializing in RNAi therapeutics, has announced the formation of a joint venture named Sagesse Bio, Inc. with US investment firm Gore Range Capital. This strategic partnership is complemented by a patent transfer and license agreement that will see Sirnaomics transferring specific intellectual property…
-
Haohai Biotech’s Sodium Hyaluronate Gel Receives NMPA Approval for Aesthetic Treatments
•
Shanghai Haohai Biology Science & Technology Co., Ltd (HKG: 6826, SHA: 688366) has announced that it has received Medical Device Registration Approval from the National Medical Products Administration for its innovative amino acid cross-linked sodium hyaluronate gel. The product is indicated for injection into the middle to deep layers of…
-
China Medical System Secures Exclusive Rights to Baiyiyuan Biotech’s Implant in Greater China
•
China Medical System Holdings (CMS; HKG: 0867) has entered into a licensing agreement with Shanghai-based Baiyiyuan Biotech, securing exclusive rights to promote, market, and commercialize Baiyiyuan’s decellularized matrix implant across Greater China, including the China mainland, Hong Kong, Macau, and Taiwan. The financial details of the agreement were not disclosed.…
-
Allergan Aesthetics’ Botox Secures New Indication for Masseter Muscle Protrusion in China
•
Allergan Aesthetics, a division of AbbVie (NYSE: ABBV), has announced that it has received approval for a new indication from the National Medical Products Administration (NMPA) for its Botox (botulinum toxin type A) product. The drug is now approved for the temporary improvement of significant or very significant masseter muscle…
-
TÜV Partners with Lancy Co., Ltd’s BRAVOU to Enhance Medical Aesthetics Services in China
•
Technischer Überwachungs-Verein (TÜV), a Germany-based international independent third-party testing, inspection, and certification organization, has entered into a partnership with the medical aesthetics unit of Chinese firm Lancy Co., Ltd (SHE: 002612), known as BRAVOU. In China, medical aesthetics services are categorized as medical care activities, a sector that has been…
-
Hymson Laser’s Mid Infrared Femtosecond Laser Technology Makes Medical Industry Inroads
•
Shenzhen-based Hymson Laser Technology Group Co., Ltd (SHA: 688559) has announced a significant breakthrough with the application of its mid-infrared femtosecond laser technology in healthcare. The company has developed a long wave infrared femtosecond laser (LWIRFS) with a wavelength range exceeding 5 μm, marking a global first in its category.…
-
Huadong Medicine’s Lidocaine-Containing Hyaluronic Acid Gel Accepted for NMPA Review
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration (NMPA) has accepted for review the market approval filing for its Category III medical device, MaiLi Extreme, a lidocaine-containing crosslinked sodium hyaluronate gel. This high-end hyaluronic acid product, which received the CE mark in June…
-
Huadong Medicine’s MaiLi Extreme Achieves Clinical Study Milestone for Chin Retraction Treatment
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that a Chinese clinical study for MaiLi Extreme, an injectable lidocaine-containing sodium hyaluronate by its UK subsidiary Sinclair, has successfully met its primary endpoint, demonstrating good safety data. The study aimed to evaluate the efficacy and safety of MaiLi Extreme injections…
-
ARSMO Plastic Aesthetic Hospital Introduces Liquid PCL Implant GOURI in Hainan
•
ARSMO Plastic Aesthetic Hospital Holding Co., Ltd. has announced the inaugural application of GOURI, a fully liquid polycaprolactone (PCL) based dermal filler, in its Hainan-based unit. GOURI is a renewable material that utilizes CESABP technology, allowing it to be fully liquid and to decompose gradually, thereby promoting the natural regeneration…
-
Jiangsu Wuzhong Pharmaceutical Partners with SPH KDL Health to Boost Aesthetics Product AestheFill
•
Jiangsu Wuzhong Pharmaceutical Group Corp., (SHA: 600200), a leading Chinese pharmaceutical company, has announced a strategic partnership agreement with domestic firm SPH KDL Health. The collaboration aims to enhance the marketing efforts of Wuzhong Pharmaceutical’s medical aesthetics subsidiary’s polylactic acid facial filler, AestheFill. The partnership encompasses commercial distribution, expansion of…
-
Jiangsu Wuzhong Pharmaceutical’s Aesthetics Subsidiary Wins Approval for Facial Filler in China
•
Jiangsu Wuzhong Pharmaceutical Group Corp., (SHA: 600200), a prominent player in the Chinese pharmaceutical industry, has announced that its medical aesthetics subsidiary’s polylactic acid facial filler, AestheFill, has received marketing approval in China. The product is slated to become available in mainland China in the first half of 2024. AestheFill,…
-
China Medical System Holdings Secures Exclusive Rights to Promote Xihong Biopharma’s Aesthetic Fillers
•
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a licensing agreement with Jiangxi Xihong Biopharma Co., Ltd, granting CMS exclusive promotion, marketing, and commercialization rights for Xihong Biopharma’s injectable polycaprolactone microspheres filler and injectable hydroxyapatite microspheres filler in China mainland, Hong Kong, Macau, and Taiwan. Both Category III…
-
Sisram Medical’s Profhilo Accepted for Review by China’s NMPA
•
Sisram Medical Ltd (HKG: 1696), an Israel-based company within the Fosun Pharmaceutical Group (SHA: 600196), has announced that its licensed injection filler product, Prohiro, has had its market filing accepted for review by China’s National Medical Products Administration (NMPA). Profhilo, an injectable sodium hyaluronate solution, is recognized as one of…
-
Huadong Medicine Co., Ltd Secures Partnership and Commercial Rights for Yuyan’s Botulinum Toxin
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an equity investment and partnership agreement with Chongqing Yuyan Pharmaceutical Co., Ltd. This strategic alliance involves a significant investment and the acquisition of exclusive commercialization rights for Yuyan’s medical aesthetics product in key regions. Investment and Stake AcquisitionAs per the…
-
Sisram Medical Ltd Expands Asia-Pacific Presence with New Direct Sales Office in Japan
•
Sisram Medical Ltd (HKG: 1696), an Israel-based company that is part of the Fosun Pharmaceutical Group, has announced that its subsidiary, Alma Lasers, has established a new direct sales channel in Japan, marking the company’s sixth direct sales office in the Asia-Pacific region. New Sales Office and Regional ExpansionThe new…
-
Huadong Medicine Secures Global Licensing Agreement for ATGC-110 Botulinum Toxin A Injection
•
China-based Huadong Medicine Co., Ltd. (SHE: 000963) has announced a strategic licensing agreement with South Korea’s ATGC, granting Huadong exclusive global rights (excluding India) to ATGC’s botulinum toxin A injection, ATGC-110. The agreement also provides a non-exclusive license for South Korea, encompassing clinical development, regulatory filing, and commercialization rights across…
-
Sihuan Pharmaceutical Reports H1 2023 Revenue Dip Amid R&D Focus
•
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its financial report for the first half of 2023, recording revenues of RMB 1.0557 billion (USD 144 million), marking a 27.9% decrease year-on-year (YOY). The research and development (R&D) expenses for the period were RMB 294 million (USD 40 million), a…
-
AbbVie’s Allergan Aesthetics Secures NMPA Approval for Juvéderm VOLUMA with Lidocaine
•
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for Juvéderm VOLUMA with Lidocaine, expanding its indications to include nose augmentation procedures. Product Description and BenefitsJuvéderm VOLUMA with Lidocaine is a cross-linked sodium hyaluronate gel designed…
-
Huadong Medicine’s Subsidiary Viora Ltd’s V20 Accepted for NMPA Review
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration (NMPA) has accepted a Category III market filing for its wholly owned subsidiary Viora Ltd’s V20 optical radiofrequency therapy instrument. This development marks a significant step forward for the company’s entry into the Chinese medical…
